Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Accured Expenses: 2014-2025

Historic Change in Accured Expenses for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -$326,000.

  • CytomX Therapeutics' Change in Accured Expenses fell 116.04% to -$326,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.1 million, marking a year-over-year decrease of 242.98%. This contributed to the annual value of -$9.6 million for FY2024, which is 36.74% down from last year.
  • Per CytomX Therapeutics' latest filing, its Change in Accured Expenses stood at -$326,000 for Q3 2025, which was up 70.44% from -$1.1 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Change in Accured Expenses registered a high of $8.1 million during Q4 2021, and its lowest value of -$7.4 million during Q1 2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$1.7 million (2024), whereas its average is -$1.8 million.
  • In the last 5 years, CytomX Therapeutics' Change in Accured Expenses spiked by 567.05% in 2021 and then crashed by 932.12% in 2023.
  • Over the past 5 years, CytomX Therapeutics' Change in Accured Expenses (Quarterly) stood at $8.1 million in 2021, then tumbled by 147.94% to -$3.9 million in 2022, then surged by 136.63% to $1.4 million in 2023, then plummeted by 490.03% to -$5.6 million in 2024, then slumped by 116.04% to -$326,000 in 2025.
  • Its Change in Accured Expenses stands at -$326,000 for Q3 2025, versus -$1.1 million for Q2 2025 and -$2.1 million for Q1 2025.